4002:TADAWULMouwasat Medical Services Co. Analysis

Mouwasat Medical Services is trading at SAR 62.2, comfortably above its 20‑day SMA of 61.36 but still below the 50‑day (63.47) and 200‑day (67.74) averages, indicating a short‑term pull‑back within a longer‑term downtrend. Technical signals are mixed: the RSI sits at a neutral 52, while the MACD histogram is positive and the MACD line has crossed above its signal, suggesting a modest bullish bias. Fundamentally, the stock appears attractively priced with a trailing PE of 15 versus an industry average of 29, a dividend yield of 6.63% and a payout ratio of 72.6%, which supports dividend sustainability. The company delivers solid profitability (operating margin 24.8%, profit margin 25.1%) and healthy cash generation (operating cash flow SAR 1.22 bn, free cash flow SAR 376 m). Revenue is growing at 9% YoY and leverage is modest (debt‑to‑equity 27.9), while the beta of just 0.077 points to very low market volatility. However, recent price action reflects a bearish trend direction with a support level near SAR 59.45 and resistance at SAR 63.05, and the 30‑day volatility of 17.5% combined with a max drawdown of 25% underscores downside risk. The DCF fair value of SAR 32.08 suggests the market is pricing in a premium, yet analyst consensus targets a median price of SAR 89, implying a potential upside of over 30%.
Overall, the combination of defensive healthcare exposure, strong dividend yield, and relative undervaluation makes Mouwasat a compelling candidate for investors seeking income and value, while the technical side advises caution until price stabilises above the immediate resistance.